Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial

Kudo, M; Lim, HY; Cheng, AL; Chao, Y; Yau, T; Ogasawara, S; Kurosaki, M; Morimoto, N; Ohkawa, K; Yamashita, T; Lee, KH; Chen, ER; Siegel, AB; Ryoo, BY

Kudo, M (corresponding author), Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan.

LIVER CANCER, 2021; 10 (3): 275